Improve

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Improve

Property Description
Active Ingredient Olmesartan Medoxomil
Form Tablet (Oral Dosage Form)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose To assist in lowering blood pressure
Origin Synthetic Prodrug

What Type of Medicine is Improve (Olmesartan Medoxomil)?

Improve is a synthetic, prescription-only medicine officially classified as an Antihypertensive Agent used to help manage high blood pressure. It belongs specifically to the Angiotensin II Receptor Blocker (ARB) class of medications, which are integral to cardiovascular therapy. The drug’s core function is to reduce vascular constriction.

ARBs like Olmesartan are used to help lower blood pressure by allowing blood to flow more easily. The specific formulation of Improve is commonly utilized in adults and may also be prescribed for pediatric patients aged six years and older, representing a distinct demographic focus within the ARB class.


Composition and Form: The Synthetic Prodrug

The core substance in Improve is the active ingredient, Olmesartan Medoxomil, which is categorized chemically as a synthetic prodrug. A prodrug is a compound that is initially inactive upon oral administration but is rapidly converted by the body’s digestive enzymes into its therapeutically active form, Olmesartan.

This structural design ensures the medication is absorbed efficiently before it becomes therapeutically active. While Improve is a specific brand, Olmesartan Medoxomil is also the active ingredient in other globally recognized products, such as Benicar and Olmetec. The drug is most commonly provided as a film-coated tablet and is also available in an oral suspension form.


How Improve Generally Affects the Body

Improve generally affects the body by interfering with the renin-angiotensin-aldosterone system (RAAS), a hormonal network central to blood pressure regulation. The medication’s active component, Olmesartan, functions as an Angiotensin II Receptor Antagonist, selectively blocking the action of the powerful, naturally occurring hormone angiotensin II. By blocking this hormone from binding to its receptors, the medication promotes vasodilation (blood vessel relaxation). This mechanism serves the general purpose of decreasing the resistance within blood vessels, thereby effectively assisting in lowering the systemic blood pressure.

Regulatory References

  1. NIH summary on ARBs

What side effects are possible with Improve?

Improve (Olmesartan Medoxomil) is associated with adverse reactions that are classified by government regulatory agencies based on frequency and affected physiological system. The adverse reaction profile is documented across standard categories such as Nervous System Disorders (e.g., dizziness, headache), Gastrointestinal Disorders (e.g., diarrhea, vomiting), and Renal and Urinary Disorders.

Documented Adverse Reaction Frequencies

Side effects are officially classified in regulatory documents:

  • Common (observed in ge 1/100 to < 1/10 patients): Dizziness, Headache, Upper respiratory tract infection, Fatigue, Bronchitis.
  • Uncommon (observed in ge 1/1,000 to < 1/100 patients): Thrombocytopenia (low platelet count), Anaphylactic reaction, Vertigo.
  • Rare (observed in ge 1/10,000 to < 1/1,000 patients): Acute renal failure, Symptomatic Hypotension (low blood pressure), Angioedema (swelling), Hyperkalaemia (high potassium).
  • Very Rare: Sprue-like enteropathy (severe, chronic diarrhea and weight loss).

Serious Safety Considerations

Official labeling highlights critical safety concerns. The medication is contraindicated in women who are pregnant, particularly during the second and third trimesters, due to the high risk of Fetal Toxicity (injury and death to the developing fetus). Rare but serious reactions include Acute Renal Failure and severe swelling known as Angioedema. The unique gastrointestinal reaction, Sprue-like enteropathy, may develop months to years after starting the treatment.

Population and Duration Constraints

Safety constraints noted in regulatory documents apply to specific populations. Use is not recommended in infants under one year of age and in patients with severe renal impairment. Additionally, Symptomatic Hypotension may be anticipated upon the initiation of treatment in volume- or salt-depleted individuals.

Overdose and Emergency Response

Overdose and when to seek help

The information below outlines the officially documented clinical signs and mandated emergency actions for Olmesartan Medoxomil overdose, strictly according to government regulatory sources. This information is descriptive and not intended as clinical advice.


Documented Overdose Manifestations

The most likely manifestations of an overdose with Olmesartan Medoxomil, a medicine used to lower blood pressure, are hypotension (abnormally low blood pressure) and tachycardia (abnormally fast heart rate). Official labeling notes that bradycardia (abnormally slow heart rate) could also occur as a result of parasympathetic stimulation.

In the event of an overdose, the primary severe outcome requiring intervention is symptomatic hypotension.


Official Emergency Actions

Regulatory authorities mandate that individuals must seek emergency medical attention immediately upon suspected overdose. If symptomatic hypotension is present, supportive treatment should be initiated immediately, which often involves placing the patient in a supine position and, if necessary, administering an intravenous infusion of normal saline to raise blood pressure.

It is officially documented that no specific antidote is known for Olmesartan Medoxomil, and the substance is not dialyzable (cannot be effectively removed by blood filtration).

Therapeutic Uses of Improve

Improve (Olmesartan Medoxomil) is commonly used in the long-term management of a condition marked by increased physiological stress. Its use is applied across therapeutic domains involving heightened systemic burden, and it contributes to preventative benefits for the patient. The medication plays a role in managing the sustained, high internal pressure within blood vessels.


What Improve Treats: Main Uses and Benefits

Improve is commonly used for the long-term management of essential hypertension (high blood pressure) in adult patients. It is also relevant for use in pediatric patients aged six years and older, and is often applied as part of a combination therapy regimen. This therapeutic approach supports efforts to reach and maintain target blood pressure goals over time.

A key aspect of its therapeutic role is providing supportive benefit for managing the risks associated with chronic high pressure. This usage is relevant for easing Wood conditions linked to organ-specific functional stress. This long-term use may assist with maintaining functional stability by addressing symptoms linked to organ-specific functional stress, contributing to overall general well-being during symptomatic phases.

Quick Fact: Relief for Vascular Strain Improve is applied across domains where additional symptomatic support is needed to ease the physical discomfort and heightened physiological activity related to chronic vascular strain.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Improve (Olmesartan Medoxomil) eligibility is strictly defined by regulatory criteria, encompassing specific age groups, physiological states, and co-existing conditions.

Contraindicated Populations

The medicine is contraindicated for several groups based on official labeling:

  • Pregnant patients in the second and third trimesters. Treatment must be discontinued as soon as possible when pregnancy is detected.
  • Patients with a known hypersensitivity to Olmesartan Medoxomil or any component of the formulation.
  • Patients with diabetes mellitus who are receiving the drug aliskiren concomitantly.
  • Patients with biliary obstruction (as defined by regulatory summaries).

Age and Organ Function Restrictions

The drug is approved for use in adults and pediatric patients aged 6 years and older. Safety and efficacy have not been established in children aged 1 to 5 years, and use is not recommended in children under 1 year of age. Use is generally not recommended for patients with severe renal impairment or severe hepatic impairment due to limited clinical experience in these specific populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for Improve (Olmesartan Medoxomil) is primarily defined by pharmacodynamic and pharmacokinetic interaction patterns documented in official governmental sources.

Interaction-Related Restrictions

Classification Interacting Agent Official Statement on Interaction
Contraindicated Aliskiren Prohibited for co-administration in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73m^2).

Official Interaction Statements

  • Dual RAS Blockade: The combination with other agents that block the Renin-Angiotensin System, such as ACE Inhibitors or Aliskiren, is generally avoided due to increased risks of hypotension, hyperkalemia, and changes in renal function.
  • Potassium-Altering Agents: Co-administration with Potassium-Sparing Diuretics (e.g., spironolactone) or Potassium Supplements is associated with an increased risk of hyperkalemia.
  • Lithium: Concomitant use with Olmesartan may cause reversible increases in serum Lithium concentrations and the potential for Lithium toxicity due to reduced renal clearance.
  • NSAIDs: The use of Non-Steroidal Anti-Inflammatory Drugs may lead to both a reduced antihypertensive effect and an increased risk of worsening renal function.
  • Colesevelam Hydrochloride: Administration of Olmesartan Medoxomil must be separated in time; it should be administered at least 4 hours before Colesevelam Hydrochloride to mitigate reduced absorption and systemic exposure of Olmesartan.

Olmesartan is not expected to have clinically relevant pharmacokinetic interactions with drugs metabolized by major Cytochrome P450 enzymes.

Mechanism of Action

Pharmacodynamic Mechanism of Improve

Improve is a small molecule that acts as a selective allosteric modulator primarily targeting the G-protein coupled receptor (GPCR) subtype X, specifically concentrating in tissue type Y. The compound binds to an allosteric site distinct from the orthosteric ligand-binding pocket, inducing a conformational change in the receptor structure.

This allosteric binding increases the affinity of the endogenous agonist for GPCR subtype X, leading to enhanced receptor activation. Enhanced activation of GPCR subtype X triggers the dissociation of the G-protein complex, releasing the alpha-subunit and the betagamma-dimer. The alpha-subunit then modulates adenylyl cyclase activity, leading to an increase in intracellular cyclic AMP (cAMP) levels.

This increase in cAMP initiates a downstream signaling cascade involving the activation of Protein Kinase A (PKA). PKA phosphorylates specific cellular substrates, which ultimately results in the modulation of ion channel activity and altered cellular membrane excitability in target cells. This chain of intracellular events constitutes the primary physiological consequence of Improve's activity at the system level.

Dosage and Administration Information

How to Use Improve (Olmesartan Medoxomil)

Improve is administered through the oral route using film-coated tablets in strengths of 5 mg, 20 mg, and 40 mg. An extemporaneously compounded oral suspension is also an available dosage form intended for pediatric patients who cannot swallow tablets.

Standard Labeled Administration

The medicine is typically taken once daily (QD), and for proper use, it should be administered at approximately the same time each day. The tablets may be taken with or without food.

Category Official Instructions (Adults)
Starting Dose 20 mg once daily
Maintenance/Maximum Dose 40 mg once daily
Dose Titration May be increased after two weeks of therapy

Population-Specific Use and Constraints

Instructions specify administration rules for certain groups. For pediatric patients (6 to <17 years), the dosing is weight-based, with maximum daily doses of 20 mg or 40 mg depending on the child’s weight. In cases of renal or moderate hepatic impairment, the maximum daily dose is typically limited to 20 mg.

Procedural Consistency

A two-week period is typically established before considering a dose adjustment, providing a defined schedule for titration. If a dose is missed, it should be taken as soon as possible unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped, ensuring doses are not doubled. The use of the oral suspension requires it to be shaken well before use and generally stored under refrigeration.

Recent Clinical Evidence

Research Evidence / Overview of studies

Overview of Key Studies on [Drug Name]

Clinical research on [Drug Name] explored the potential to affect symptoms in patients with Condition X. Studies examined the change in the frequency and severity of flare-ups compared to placebo.

  • Study A (Phase 3 RCT): This pivotal trial of 500 patients evaluated whether the drug was associated with a change in outcomes, focusing on potential changes in inflammatory markers. The study examined the time to symptom change, and the study included a comparison group receiving standard-of-care treatments for mild-to-moderate cases. The study design specified a protocol for initiation of the drug.
  • Study B (Observational Cohort): This long-term study gathered data on the safety profile. Researchers reported that the study’s safety data included observations over the long term in adults. Research examined the frequency of long-term complications associated with Condition X. The study protocol documented the need for specific monitoring.

Combination Therapy and Special Populations

Research has also explored the use of [Drug Name] in combination with other therapies.

  • Combination with Drug Y: A small phase 2 trial evaluated whether the combination was associated with a change in quality of life and examined changes in reported pain levels compared to monotherapy. This combination was the focus of evaluation in participants with severe, refractory Condition X.
  • Special Populations: Evidence remains limited, but a small study in adolescents examined the drug’s profile and observed an outcome similar to that seen in adults. The study included specific exclusion criteria for pre-existing medical conditions.

Key Studies & References

  1. Pharmacokinetic and Pharmacodynamic Study of [Drug Name] and Drug Y Combination Therapy in Refractory Cases of Condition X (Phase 2)
  2. Clinical Guideline for the Management of Condition X in Adults and Pediatric Populations (Relevant National Society/WHO)

Frequently Asked Questions (FAQ)

Common questions about Improve (FAQ)


Q: How long does it usually take for Improve's effects to be noticeable?

Official studies indicate that the full blood pressure-lowering effect is generally achieved within 2 weeks after starting treatment. However, the maximum reduction in blood pressure is often observed after about 8 weeks of therapy, and individual patient response times may vary.


Q: Is Improve meant to be a short-term or long-term medication?

Improve is used to manage high blood pressure, which is typically a long-term or chronic condition and the medication is indicated for chronic use. Regulatory documents categorize this type of use as continuous management for the approved population.


Q: Can Improve cause weight gain or weight loss?

Unusual weight loss or weight gain have been reported as rare side effects in official safety documents. In some cases, severe, chronic diarrhea associated with this medication may lead to substantial weight loss.


Q: Does Improve interact with supplements like vitamins or herbal remedies?

Official documentation specifically warns against combining this medication with potassium supplements or salt substitutes that contain potassium, due to the risk of high potassium levels. Official regulatory text describes the importance of a patient's healthcare provider being aware of all concurrent supplements and herbal remedies being used, due to the potential for interaction risks.


Q: Is it possible to take Improve while breastfeeding?

Official labeling advises that the active ingredient, olmesartan, is not recommended during breastfeeding. A decision must be made by a healthcare professional regarding whether to discontinue nursing or discontinue the drug, based on the medication’s necessity for the mother.


Q: Are there any known issues with taking Improve before surgery?

Regulatory information indicates that this medication may cause severe hypotension (very low blood pressure) during anaesthesia or surgery. Regulatory guidance describes that the medicine is often omitted on the morning of surgery to mitigate this risk.


Q: Is it normal to feel a bit nauseous when first starting Improve?

According to official product information, nausea is listed as a common gastrointestinal side effect observed in a small percentage (between 1% and 10%) of patients in clinical trials.


Q: What should I do if a side effect doesn't go away?

Official regulatory guidance requires immediate medical attention for serious side effects. If a common side effect (like headache or dizziness) persists or becomes troublesome, official labeling indicates that consultation with a healthcare provider is appropriate.


Q: Is there evidence that Improve works better for some people than others?

Studies show that the drug's effectiveness can be influenced by factors like weight (in children) and there are sometimes differences in response based on race or salt-sensitivity. Despite these variations, overall efficacy is demonstrated across the approved patient population.


Q: How long after stopping Improve will it be fully out of my system?

Official pharmacokinetic studies show that the active substance, olmesartan, has a terminal elimination half-life of approximately 13 hours. Most of the substance is generally eliminated from the body after about mathbf4 mathbfto mathbf5 mathbfhalf-mathbflives, which is a standard pharmaceutical measurement.


Q: What are the ingredients in Improve besides the active compound?

The official prescribing information for the product details the complete list of mathbfinactive mathbfingredients (excipients). These ingredients are standard components that help form the tablet or suspension, such as microcrystalline cellulose, lactose, and titanium dioxide.


Q: Are there any reports of Improve causing mental fog or difficulty concentrating?

While specific symptoms like 'mental fog' or 'difficulty concentrating' are not officially listed, headache and dizziness are common adverse effects. These common adverse effects are officially documented as potential safety concerns that may result in altered focus.


Q: Have there been any major warnings or recalls for Improve?

Official labeling includes a mathbfBoxed mathbfWarning regarding mathbfFetal mathbfToxicity (severe harm to an unborn baby). Separately, regulatory bodies may issue product mathbfrecalls periodically for reasons such as packaging, contamination, or manufacturing errors.


Q: What happens if Improve is taken with alcohol?

Taking this medication with mathbfalcohol may mathbfincrease the risk of mathbflow mathbfblood mathbfpressure (hypotension). This can lead to symptoms like mathbfdizziness, mathbflightheadedness, or mathbffainting. Official guidance emphasizes that consumption of alcohol should be discussed with a healthcare professional.


Q: What percentage of people see an improvement when taking this medication?

Official clinical trial summaries report efficacy primarily as a mathbfmean mathbfchange in blood pressure (mathbfmmHg) compared to placebo. This is a standard practice in regulatory reporting and provides a measure of the overall treatment effect rather than a simple percentage of individual responders.


Q: Do studies suggest Improve's effect diminishes over time?

Regulatory data indicates that the maximum blood pressure-lowering effect is often seen after eight weeks and is generally mathbfsustained during mathbflong-mathbfterm therapy. The official product information does not indicate a loss of blood pressure-lowering effect (tachyphylaxis).


Q: Can Improve be taken with cold and flu medications?

The medication mathbfinteracts with mathbfNon-mathbfSteroidal mathbfAnti-mathbfInflammatory mathbfDrugs (mathbfNSAIDs), which are frequently found in cold and flu remedies. Additionally, mathbfsome ingredients in non-specific cold medications may potentially mathbfincrease mathbfblood mathbfpressure. Review of all ingredients with a healthcare provider is necessary due to the potential for adverse interactions.


Q: Are there clinical guidelines that describe when to stop using Improve?

Yes, official guidelines mandate that the medicine mathbfmust mathbfbe mathbfdiscontinued mathbfimmediately when mathbfpregnancy is detected. Discontinuation may also be considered in cases of severe side effects, such as mathbfacute mathbfrenal mathbffailure or mathbfSprue-mathbflike mathbfenteropathy (severe diarrhea).


Q: Do any official sources suggest Improve causes insomnia or sleep issues?

Yes, official adverse reactions documents indicate that mathbfinsomnia (trouble sleeping) has been reported as an adverse event associated with the use of the drug in some clinical trial settings.


Q: How is Improve different from other common medications used for the same purpose?

Improve is classified as an mathbfAngiotensin mathbfII mathbfReceptor mathbfBlocker (mathbfARB), which works by mathbfselectively mathbfblocking the mathbfAT1 mathbfreceptor. This is functionally distinct from a common alternative class, the mathbfACE mathbfinhibitors, which work by mathbfblocking the mathbfproduction of Angiotensin II.


Q: What kind of studies were done to show how Improve works?

The mathbfmechanism mathbfof mathbfaction is established through mathbfpharmacodynamic mathbfstudies detailed in regulatory documents. These studies demonstrate that the active component, Olmesartan, mathbfselectively mathbfblocks the mathbfAT1 mathbfreceptor to lower blood pressure.


Q: Are the side effects of Improve usually mild or severe?

Regulatory data classifies the mathbfmajority of reported adverse events as Common (like dizziness, headache) or Uncommon, which are generally mild to moderate in nature. However, it is important to note that rare but serious events (such as angioedema) are also officially documented.


Q: Are there any specific foods or drinks I need to avoid while on Improve?

The tablets may be taken mathbfwith mathbfor mathbfwithout mathbffood. However, due to the risk of mathbfhyperkalemia (high potassium), official documents caution against the co-administration of potassium supplements and salt substitutes.


Q: Can older adults use Improve?

The medication is approved for use in mathbfadults. Official labeling advises mathbfcaution and mathbfmonitoring in all elderly patients, especially those with mathbfpre-mathbfexisting mathbfconditions, though specific dose adjustments are not universally required for all older adults.


Q: Are there different restrictions for using Improve based on gender?

The only official restriction based on gender is the mathbfcontraindication for use in mathbfpregnant mathbfwomen during the second and third trimesters. No gender-specific restrictions are listed in regulatory documents for adult male patients.


Q: Does Improve need to be stored in the refrigerator?

The mathbftablets should be stored at mathbfControlled mathbfRoom mathbfTemperature (between 20 C and 25 C). However, the mathbforal mathbfsuspension form, which is prepared by a pharmacist, typically mathbfrequires mathbfrefrigeration to maintain its stability.


Q: Can I take Improve at any time of day?

Official instructions state that the medication should be taken mathbfonce mathbfdaily at mathbfapproximately mathbfthe mathbfsame mathbftime mathbfeach mathbfday for consistent dosing. The specific time of day is determined based on individual patient needs and provider guidance, with the emphasis on consistency.


Q: Does Improve affect my ability to drive or operate machinery?

Because the medication may cause mathbfdizziness or mathbffatigue as side effects, official documents warn that it may impair the ability to mathbfdrive or mathbfoperate mathbfmachinery, particularly when treatment is first initiated or the dose is changed.


Q: How can I know if Improve is actually working for me?

The primary regulatory method to assess the drug’s effectiveness is through the regular monitoring of blood pressure, which is carried out under the guidance of a healthcare provider. Additionally, the disappearance of certain symptoms or the experience of side effects like dizziness can be indirect signs that the medication is lowering blood pressure.


Q: What is the difference between the generic and brand name versions of Improve?

The generic version contains the mathbfidentical mathbfactive mathbfingredient (mathbfOlmesartan mathbfMedoxomil) in the same strength and dosage form as the brand name. The FDA and other regulators require generic products to meet the same strict standards for mathbfquality, mathbfpurity, mathbfand mathbfeffectiveness as the original brand product.


Q: Is it necessary to have routine blood work done while taking Improve?

Due to the potential for this medication to cause changes in mathbfrenal mathbffunction and mathbfhyperkalemia (high potassium), official labeling advises that mathbfblood mathbftests may be mathbfneeded mathbfregularly to monitor your mathbfkidney mathbffunction and mathbfpotassium mathbflevels.

How should Improve be stored and disposed of?

How to Store and Dispose of Improve

Improve (Olmesartan Medoxomil) tablets must be stored according to official regulatory conditions to maintain stability and potency.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F).
Protection Keep the medicine in its original container, tightly closed, to protect from moisture and light. Do not freeze.
Safety Keep Improve tablets out of the sight and reach of children.

Disposal Instructions

Dispose of any unused or expired Improve according to local laws and regulations for pharmaceutical waste. Do not flush the tablets down the toilet or pour them into a drain. Utilize authorized drug take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Improve found in:

A-Z Index: